Opening subject page...
Loading your content
Systematic approaches to identifying and treating life-threatening dysrhythmias in the prehospital and emergency setting.
The ability to recognize and treat abnormal heart rates has been a defining challenge in emergency medicine for over a century. Before the advent of cardiac monitoring, clinicians relied solely on pulse palpation and auscultation to identify bradycardia (abnormally slow heart rate) and tachycardia (abnormally fast heart rate), two conditions that can rapidly deteriorate into cardiac arrest if left untreated. The evolution from crude pharmacological interventions to today's evidence-based ACLS algorithms represents decades of clinical research, technological breakthroughs, and iterative guideline development by organizations such as the American Heart Association.
The central question that drives modern dysrhythmia management remains fundamentally the same question that Einthoven's work first made answerable: Is this patient's heart rate adequate to maintain perfusion, and if not, what is the fastest, safest intervention to restore hemodynamic stability? The ACLS bradycardia and tachycardia algorithms provide paramedics with a structured decision framework to answer this question rapidly, even under the immense pressure of a prehospital emergency.
Effective dysrhythmia management rests on a small number of foundational principles that guide every clinical decision, from the initial rhythm interpretation on the cardiac monitor to the choice between pharmacological and electrical therapy. These principles unify the bradycardia and tachycardia algorithms into a coherent clinical framework. A paramedic must internalize these concepts so deeply that they become reflexive, because the time between recognition and intervention is often measured in minutes—or less.
The bradycardia algorithm begins with the recognition that a heart rate below 60 beats per minute may or may not be clinically significant. The critical branch point in the algorithm is the assessment of hemodynamic instability, which is defined by the presence of hypotension, altered mental status, signs of shock, ischemic chest discomfort, or acute heart failure. If the patient is stable, the paramedic continues to monitor and transports the patient without aggressive intervention. If the patient is unstable, the first-line pharmacological agent is atropine, administered at 1 mg intravenously, which may be repeated every 3 to 5 minutes to a maximum dose of 3 mg. Atropine works by blocking vagal (parasympathetic) tone on the sinoatrial and atrioventricular nodes. If atropine proves ineffective—particularly in cases of high-degree AV block or infranodal block—the algorithm directs the provider to transcutaneous pacing or a continuous infusion of dopamine (typically 5–20 μg/kg/min) or epinephrine (2–10 μg/min).
Understanding the mechanism of each intervention is essential for anticipating its effects and limitations. Atropine sulfate is a competitive antagonist at muscarinic (M₂) receptors in the heart. Because the parasympathetic vagus nerve exerts tonic inhibitory influence on the SA and AV nodes, blocking this input with atropine accelerates the firing rate of the SA node and improves AV conduction. Critically, atropine is ineffective in patients with infranodal (below the AV node) block, because the parasympathetic nervous system exerts minimal influence below the bundle of His. In these patients, transcutaneous pacing becomes the primary intervention.
For stable narrow-complex tachycardia, adenosine is the drug of choice. Adenosine transiently blocks conduction through the AV node by activating potassium channels and inhibiting calcium influx, effectively "resetting" re-entrant circuits that pass through the AV node (as in AVNRT and AVRT). Its half-life is less than 10 seconds, so it must be administered as a rapid IV push followed by a normal saline flush. The initial dose is 6 mg; if ineffective, 12 mg may be given and repeated once. For stable wide-complex tachycardia or polymorphic VT, amiodarone (150 mg IV over 10 minutes) is preferred, as it blocks sodium, potassium, and calcium channels while also possessing beta-blocking activity. Procainamide (20–50 mg/min IV) is an alternative for monomorphic VT in hemodynamically stable patients.
When pharmacological measures fail or when the patient is hemodynamically unstable with tachycardia, synchronized cardioversion is the definitive intervention. Synchronization means the defibrillator senses the R wave and delivers the shock during the refractory period, avoiding the vulnerable period of the T wave that could precipitate ventricular fibrillation. Initial energy settings vary by rhythm: narrow-complex rhythms typically begin at 50–100 J (biphasic), while wide-complex rhythms begin at 100 J with escalation as needed. For unstable bradycardia, transcutaneous pacing delivers a controlled electrical impulse through pads on the chest wall to directly stimulate myocardial depolarization, with the output typically starting at 60 mA and titrated upward until electrical capture (concordance between pacer spike and QRS complex) is achieved.
The tachycardia algorithm is more branched than the bradycardia algorithm because the differential diagnosis of a fast heart rate is considerably broader. The first decision remains the same—is the patient hemodynamically stable? If the answer is no, proceed immediately to synchronized cardioversion. If the patient is stable, the second question is QRS width. A narrow QRS (< 0.12 seconds) suggests a supraventricular tachycardia (SVT), which is further subdivided into regular SVT (likely AVNRT or AVRT, treated with vagal maneuvers and adenosine) or irregular SVT (likely atrial fibrillation, treated with rate control agents such as diltiazem or beta-blockers). A wide QRS (≥ 0.12 seconds) suggests possible ventricular tachycardia (VT) or SVT with aberrant conduction; regular wide-complex tachycardia is assumed to be VT until proven otherwise and is treated with amiodarone or procainamide.
| Drug / Intervention | Indication | Dose | Key Limitations |
|---|---|---|---|
| Atropine | Symptomatic bradycardia (1st line) | 1 mg IV q3–5 min; max 3 mg | Ineffective in infranodal block (Mobitz II, 3rd-degree); avoid in transplant hearts (denervated) |
| Dopamine infusion | Bradycardia refractory to atropine | 5–20 μg/kg/min IV | May cause tachyarrhythmias at high doses; requires infusion pump |
| Epinephrine infusion | Bradycardia refractory to atropine | 2–10 μg/min IV | Potent vasopressor; may increase myocardial O₂ demand and ischemia |
| Adenosine | Stable regular narrow-complex SVT | 6 mg rapid IVP → 12 mg → 12 mg | Ultra-short half-life (<10 s); must use rapid push + flush; contraindicated in wide-complex of unknown origin |
| Amiodarone | Stable wide-complex VT; refractory SVT | 150 mg IV over 10 min; may repeat | Hypotension during infusion; long half-life (40–55 days); QT prolongation |
| Synchronized Cardioversion | Unstable tachycardia with pulse | Narrow: 50–100 J; Wide: 100 J; escalate | Requires sedation if conscious; may not convert atrial fibrillation; risks VF if sync fails |
| Transcutaneous Pacing | Unstable bradycardia refractory to atropine | Rate 60–80 bpm; output titrated to capture | Painful (requires analgesia/sedation); may not achieve capture; temporary bridge only |
While the ACLS bradycardia and tachycardia algorithms represent the standard of care for prehospital and emergency department management, they serve as the foundation for more advanced cardiac interventions encountered in critical care medicine and interventional cardiology. Understanding where these algorithms connect to advanced practice ensures that the paramedic can anticipate the trajectory of care for their patient and facilitate seamless transitions to the receiving team.
| Paramedic-Level Intervention | Advanced / In-Hospital Continuation |
|---|---|
| Transcutaneous pacing for symptomatic bradycardia | Transvenous pacing — catheter-based pacing wire advanced into the right ventricle for more reliable capture and patient comfort; bridge to permanent pacemaker implantation |
| Adenosine for regular narrow-complex SVT | Electrophysiology (EP) study & catheter ablation — invasive mapping and destruction of accessory pathways or ectopic foci causing recurrent SVT (definitive cure) |
| Amiodarone for monomorphic VT | Implantable cardioverter-defibrillator (ICD) — device implantation for patients at high risk of recurrent VT/VF; provides automatic defibrillation |
| Synchronized cardioversion for unstable AFib/flutter | Rhythm vs. rate control strategy — long-term management decision involving anticoagulation, anti-arrhythmic drugs, or pulmonary vein isolation |
| Identification of Torsades de Pointes (polymorphic VT with long QT) | IV magnesium sulfate 1–2 g and overdrive pacing; genetic testing for congenital long QT syndromes; isoproterenol infusion in refractory cases |
As the scope of prehospital care continues to expand, paramedics are increasingly expected to recognize conditions like Brugada syndrome, Wolff-Parkinson-White (WPW) pattern, and acquired QT prolongation on 12-lead ECG, even if definitive management occurs in the hospital. Familiarity with these entities enhances the paramedic's ability to make informed transport decisions and provide critical information during the handoff report, ultimately improving patient outcomes.
Management of bradycardia and tachycardia follows structured ACLS algorithms built around one pivotal question: is the patient hemodynamically stable? For bradycardia (HR < 60 bpm), atropine 1 mg IV is first-line therapy for unstable patients, followed by transcutaneous pacing or vasopressor infusions (dopamine or epinephrine) when atropine is ineffective. Remember that atropine is unlikely to work for infranodal blocks (Mobitz type II, third-degree AV block).
For tachycardia (HR > 100 bpm with a pulse), unstable patients receive immediate synchronized cardioversion. Stable patients are classified by QRS width (narrow vs. wide) and regularity. Regular narrow-complex SVT is treated with vagal maneuvers and adenosine; wide-complex tachycardia of uncertain origin is treated as VT with amiodarone or procainamide. The overarching principle remains constant: treat the patient, not the monitor—clinical context and hemodynamic status always guide decision-making over numeric thresholds alone.